08.04.25 -- Relationship Equity With CDMOs Is Real, Take It From A Packaging Pro

Review advice to pharma companies on three key areas of auto-injector device development: patient-centered design, container and device considerations, and manufacturing partner selection.

Learn how to carry out an effective technical and quality assessment and what specific criteria to prioritize when selecting a sterile injectable CMO partner.

Explore how a culture — rooted in accountability, collaboration, and proactive risk management — can drive operational excellence and long-term success.

Live biotherapeutic products use live microorganisms or yeast as active agents to prevent or treat diseases. For pharma manufacturers entering this emerging field, understanding the unique GMP requirements is critical.

Observe how needle innovations, including shorter needles with ultra-thin wall technology, support the delivery of drugs with greater volume, which enhances the end-user experience.

High-quality process development aims to maintain a consistent process from toxicology through to GMP production runs, and can be aided by a capable, adaptable CDMO.

Delve into the cutting-edge technologies driving the shift to microbial expression and how the right outsourcing partner can help you leverage the benefits of these innovative therapeutics.

Examine results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications.

Consider why customers consistently state that access to near real-time data is crucial to their ability to make timely, informed decisions, especially during early development.

Read why it is essential for biotechs to pick the proper contract development manufacturer for success in this market landscape.

To accelerate COVID-19 vaccine production, a leading biologics contract manufacturer sought high-speed labeling machines that could be rapidly deployed.

Reconstituted nasal epithelium (RNE) offers a human-relevant model for nasal drug delivery, outperforming frozen mucosa and aligning better with clinical outcomes for opioid formulations.

Strategically upgrade your upstream and downstream processes and decrease the timeline to commercial manufacturing.

With expertise in process optimization, analytics, and regulatory strategy, we help partners de-risk development, accelerate time to market, and ensure manufacturability from the outset.

Pionyr Immunotherapeutics, a biotech company with a pipeline of first-in-class, clinical-stage cancer immunotherapies, needed a CDMO to help rapidly develop a third lead candidate from the start.

On-site labs with our own personnel offer greater control of samples and timelines, minimizing risk for our customers.

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

Discover how our campus can support your pharmaceutical development needs with cutting-edge capabilities, an expert team, and seamless global project transfer.